Color-tunable AIE-active conjugated polymer nanoparticles as drug carriers for self-indicating cancer therapy via intramolecular FRET mechanism
Color-tunable AIE-active conjugated polymer nanoparticles as drug carriers for self-indicating cancer therapy via intramolecular FRET mechanism
复制标题
颜色可调的 AIE 活性共轭聚合物纳米粒子作为药物载体，通过分子内 FRET 机制进行自我指示癌症治疗
DOI：
10.1039/c8py00329g
复制
发表时间：
2018
影响因子：
4.6
通讯作者：
Yixiang Cheng
中科院分区：
文献类型：
--
作者：
Ziyu Wang;Cheng Wang;Yayun Wang;Hong Yuan;Yiwu Quan;Yixiang Cheng
本文采用钯催化的Suzuki偶联聚合反应合成了两种新型的AIE活性共轭聚合物。有趣的是，所获得的共轭聚合物可以通过调节它们的分子内FRET对来表现出清晰的颜色可调的AIE行为。其中，仅具有一个分子内FRET对的P-1表现出清晰的绿色AIE荧光。随着TPE部分和DTBT部分的第二分子内FRET对的加入（P-2），AIE荧光颜色可以从绿色调谐到红色。斯托克斯位移也从125 nm急剧增加到255 nm。此外，这些AIE活性聚合物可以在水体系中形成稳定的共轭聚合物纳米颗粒（CPN），并作为紫杉醇（PTX）的药物载体。最重要的是，PTX可以从这些具有AIE活性的CPN中充分释放，并对HeLa和A549细胞显示出有效的细胞毒性。特别是，这两种具有AIE活性的药物载体被细胞内化，并且它们还以绿色或红色AIE荧光显示它们的位置。本研究为设计基于颜色可调的AIE活性CPN的药物载体提供了一种新的策略，用于通过改变分子内FRET对进行自我指示的癌症治疗。
In this paper, two novel AIE-active conjugated polymers were synthesized by Pd-catalyzed Suzuki coupling polymerization reaction. Interestingly, the obtained conjugated polymers could exhibit clear color-tunable AIE behavior by adjusting their intramolecular FRET pairs. Among them, P-1 with only one intramolecular FRET pair exhibited clear green-colored AIE fluorescence. As the second intramolecular FRET pair of a TPE moiety and a DTBT moiety was added (P-2), the AIE fluorescence color could be tuned from green to red. The Stokes shift also sharply increased from 125 nm to 255 nm. Furthermore, these AIE-active polymers could form stable conjugated polymer nanoparticles (CPNs) in an aqueous system and act as drug carriers for paclitaxel (PTX). Most importantly, PTX could be sufficiently released from these AIE-active CPNs and showed effective cytotoxicity on HeLa and A549 cells. Especially, these two AIE-active drug carriers were internalized by cells, and they also revealed their location with green or red colored AIE fluorescence. This study can provide a novel strategy for designing color-tunable AIE-active CPN-based drug carriers for self-indicating cancer therapy via changing intramolecular FRET pairs.